Format

Send to

Choose Destination
Clin Transl Oncol. 2016 Dec;18(12):1221-1228. doi: 10.1007/s12094-016-1579-9. Epub 2016 Nov 28.

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

Author information

1
Department of Medical Oncology, Instituto Valenciano de Oncología, IVO, Valencia, Spain.
2
Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
3
Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
4
Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain.
5
Department of Medical Oncology, Complejo Hospitalario de Navarra, Navarre, Spain.
6
Musculoskeletal and Gastric Tumor Unit, Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
7
Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Badalona, Hospital Germans Trias i Pujol, Badalona, Spain.
8
Department of Medical Oncology, Hospital Universitario Virgen Macarena, Badalona, Spain.
9
Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Girona, Hospital Josep Trueta, Girona, Spain.
10
Department of Medical Oncology and Insituto de Biomedicina, IBIS, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain. jmartin@mustbesevilla.org.

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.

KEYWORDS:

GIST; Imatinib; Regorafenib; Sunitinib

PMID:
27896638
PMCID:
PMC5138245
DOI:
10.1007/s12094-016-1579-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center